| Bid Price | High Price | ||
|---|---|---|---|
| Ask Price | Low Price | ||
| Open Price | Spread | ||
| Prev Close | Volume |
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 20, 2019 | 5,885.00 | 5,899.00 | 5,792.00 | 5,824.00 | 2,118,164 |
| May 17, 2019 | 5,874.00 | 5,906.00 | 5,830.97 | 5,875.00 | 1,232,891 |
| May 16, 2019 | 5,816.00 | 5,881.00 | 5,772.00 | 5,880.00 | 1,691,680 |
| May 15, 2019 | 5,806.00 | 5,837.00 | 5,763.00 | 5,821.00 | 1,351,034 |
| May 14, 2019 | 5,711.00 | 5,831.00 | 5,700.00 | 5,803.00 | 2,177,586 |
| Name | AstraZeneca | Epic | AZN |
|---|---|---|---|
| ISIN | GB0009895292 | Currency | GBX |
| Type | Equity | Trading Segment | SET1 |
| Record Status | Active | Trading Status | Regular Trading |
| Industry | Health Care | Sector | Pharmaceuticals |
| EMS | 300 | Prev Close | 5,824.00 |
| Shares in Issue (m) | 1,311.76 | Market Cap (£m) | 76,901.88 |
| PE Ratio | 34.49 | Div per Share (p) | 215.20 |
| Div Yield | 3.67 | Div Cover | 0.79 |
| EPS | 170.00 | EPS Growth (%) | -28.27 |
| PEG | -1.22 | DPS Growth (%) | 6.27 |
| ROCE | 4.49 | Net Gearing | 68.88 |
| Quick Ratio | 0.78 | Current Ratio | 0.96 |
| Date | Broker | Recomm. | Price | Old Target | New Target | Notes |
|---|---|---|---|---|---|---|
| 17 May | UBS | Sell | 5,823.50 | 5,400.00 | - | Unchanged |
| 16 May | UBS | Sell | 5,823.50 | 5,400.00 | - | Unchanged |
| 13 May | UBS | Sell | 5,823.50 | 5,400.00 | - | Unchanged |
| 13 May | Citigroup | Buy | 5,823.50 | 7,000.00 | - | Reiterates |
| 10 May | Shore Capital | Buy | 5,823.50 | - | - | Reiterates |
| Date | Director | Type | Volume / Price | Trade Value |
|---|---|---|---|---|
| 08 May 2019 | Marc Dunoyer | Buy | 8,500 @ 5,800.00p | £493,000.00 |
| 02 May 2019 | Pascal Soriot | Buy | 17,100 @ 5,825.00p | £996,075.00 |
| 02 May 2019 | Philip Broadley | Buy | 520 @ 5,738.00p | £29,837.60 |
| 01 May 2019 | Pascal Soriot | Buy | 17,100 @ 5,825.50p | £996,160.50 |
| 01 May 2019 | Philip Broadley | Buy | 520 @ 5,738.00p | £29,837.60 |
